Wedbush Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)

Wedbush assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $8.00 price target on the biotechnology company's stock. Wedbush also issued estimates for Aclaris Therapeutics' Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.35) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($1.11) EPS.

A number of other equities analysts have also weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target (down previously from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Scotiabank reduced their target price on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th. Wall Street Zen lowered shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Finally, Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an "overweight" rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $9.71.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS traded down $0.01 during mid-day trading on Wednesday, hitting $1.45. 750,839 shares of the company's stock traded hands, compared to its average volume of 1,192,965. The company has a market cap of $157.01 million, a PE ratio of -2.79 and a beta of 0.42. The firm's 50 day simple moving average is $1.30 and its 200 day simple moving average is $2.16. Aclaris Therapeutics has a 1 year low of $0.99 and a 1 year high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, research analysts expect that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC lifted its stake in shares of Aclaris Therapeutics by 25.9% in the first quarter. Acadian Asset Management LLC now owns 2,195,191 shares of the biotechnology company's stock worth $3,355,000 after acquiring an additional 451,044 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aclaris Therapeutics by 29.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company's stock valued at $851,000 after purchasing an additional 127,366 shares in the last quarter. Millennium Management LLC lifted its holdings in Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company's stock worth $6,325,000 after buying an additional 2,175,101 shares during the last quarter. Palo Alto Investors LP raised its position in shares of Aclaris Therapeutics by 36.2% during the 1st quarter. Palo Alto Investors LP now owns 776,028 shares of the biotechnology company's stock valued at $1,187,000 after acquiring an additional 206,196 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at approximately $72,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.